Literature DB >> 20010590

The obviousness rejection as a barrier to biotech patent prosecution.

Shyh-Jen Wang1.   

Abstract

Mesh：

Year:  2009        PMID： 20010590     DOI： 10.1038/nbt1209-1125

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Combine and conquer: handling biotech combination inventions in the wake of KSR.

Authors:  Ha Kung Wong; Dana Lau
Journal:  Nat Biotechnol       Date:  2009-05       Impact factor: 54.908
  1 in total
  4 in total

1.  The shadow of inequitable conduct in the US patent application.

Authors:  Bao-Chi Chang; Shyh-Jen Wang
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

Review 2.  Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSR.

Authors:  Fangyu Lin; Shyh-Jen Wang
Journal:  Hum Vaccin Immunother       Date:  2013-07-30       Impact factor: 3.452

3.  Patent portfolios for biotech inventions.

Authors:  Shyh-Jen Wang
Journal:  Nat Biotechnol       Date:  2013-06       Impact factor: 54.908

4.  The "real world" barriers and solutions to Candida vaccine patent prosecutions: an analysis of U.S. Patent and Trademark Office actions on related applications.

Authors:  Shyh-Jen Wang
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.